Advertisement
Genprex, Inc.

Genprex, Inc. Fundamental Analysis

GNPXNASDAQ
HealthcareBiotechnology
$0.67
$0.006(0.86%)
U.S. Market opens in 3h 21m
Advertisement

Genprex, Inc. Fundamental Analysis

Genprex, Inc. (GNPX) shows weak financial fundamentals with a PE ratio of -0.28, profit margin of 0.00%, and ROE of -2.47%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position390.30%
PEG Ratio-0.00
Current Ratio5.61

Areas of Concern

ROE-2.47%
Operating Margin0.00%
We analyze GNPX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -220.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-220.4/100

We analyze GNPX's fundamental strength across five key dimensions:

Efficiency Score

Weak

GNPX struggles to generate sufficient returns from assets.

ROA > 10%
-82.37%

Valuation Score

Excellent

GNPX trades at attractive valuation levels.

PE < 25
-0.28
PEG Ratio < 2
-0.00

Growth Score

Weak

GNPX faces weak or negative growth trends.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
-235.45%

Financial Health Score

Excellent

GNPX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
5.61

Profitability Score

Weak

GNPX struggles to sustain strong margins.

ROE > 15%
-247.33%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is GNPX Expensive or Cheap?

P/E Ratio

GNPX trades at -0.28 times earnings. This suggests potential undervaluation.

-0.28

PEG Ratio

When adjusting for growth, GNPX's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Genprex, Inc. at 0.27 times its book value. This may indicate undervaluation.

0.27

EV/EBITDA

Enterprise value stands at -1.19 times EBITDA. This is generally considered low.

-1.19

How Well Does GNPX Make Money?

Net Profit Margin

For every $100 in sales, Genprex, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-2.47 in profit for every $100 of shareholder equity.

-2.47%

ROA

Genprex, Inc. generates $-82.37 in profit for every $100 in assets, demonstrating efficient asset deployment.

-82.37%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-2.06 in free cash annually.

$-2.06

FCF Yield

GNPX converts -13.11% of its market value into free cash.

-13.11%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.28

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.27

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.61

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-2.47

vs 25 benchmark

ROA

Return on assets percentage

-0.82

vs 25 benchmark

ROCE

Return on capital employed

-0.95

vs 25 benchmark

How GNPX Stacks Against Its Sector Peers

MetricGNPX ValueSector AveragePerformance
P/E Ratio-0.2829.34 Better (Cheaper)
ROE-247.33%688.00% Weak
Net Margin0.00%-52372.00% (disorted) Weak
Debt/Equity0.000.49 Strong (Low Leverage)
Current Ratio5.614.37 Strong Liquidity
ROA-82.37%-20476.00% (disorted) Weak

GNPX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Genprex, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-19943.84%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

75.25%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ